Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Bydgoszcz – page 38

723 clinical trials in Bydgoszcz, Poland across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Bydgoszcz at a glance
723
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

723 trials in Bydgoszcz

Open in trial search

Diabetic retinal oedema

Not recruiting

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Eye103
  • Sponsor:Eyebiotech Limited

Varicella

Not recruiting

Study on the Safety of a New Chickenpox Vaccine (GSKVX000000025896) Compared to Varicella Virus Oka/Merck Strain in Healthy Children Aged 12-15 Months

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Meningococcal immunisation

Not recruiting

Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers
  • Substances:RNMB1
  • Sponsor:Sanofi Vaccines US Inc.

Meningitis meningococcal

Not recruiting

Study on the Safety and Immune Response of MenABCWY Vaccine and Drug Combination in Healthy Infants with Meningococcal Infections

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000017986
  • Sponsor:GlaxoSmithKline Biologicals

Pneumococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal Polysaccharide Serotype 1
  • Sponsor:Sanofi Vaccines US Inc.

Pneumococcal infection

Not recruiting

Study on the Safety and Immune Response of PF-07831695 and a Drug Combination for Pneumococcal Infections in Healthy Toddlers Aged 12-15 Months

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal Polysaccharide Serotype 3 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
  • Sponsor:Pfizer Inc.

Meningococcal infection

Not recruiting

Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers
  • Substances:N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
  • Sponsor:Sanofi Pasteur

Respiratory syncytial virus infection

Not recruiting

Study on the Safety and Effectiveness of MK-1654 for Preventing Respiratory Syncytial Virus (RSV) in Healthy Pre-Term and Full-Term Infants

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers
  • Sponsor:Merck Sharp & Dohme LLC

Neovascular age-related macular degeneration

Not recruiting

Study Comparing EYP-1901 and Aflibercept for Patients with Wet Age-Related Macular Degeneration

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.

Hidradenitis

Not recruiting

Study on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Myasthenia gravis

Not recruiting

Study on the Effects of Remibrutinib for Patients with Generalized Myasthenia Gravis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of Zasocitinib (TAK-279) for Patients with Active Psoriatic Arthritis with Previous Biologic Treatment

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Bydgoszcz

What the registry says about research in the country

01 Respiratory & Infectious Diseases

Innovative clinical trials focusing on respiratory syncytial virus (RSV) and pneumococcal infections in both adults and children. Studies include vaccine development for multiple age groups and assessment of immune responses.

  • RSV and Metapneumovirus Prevention
  • Pneumococcal Vaccine Development
  • COPD Treatment Innovation

Research emphasizes preventive measures and vaccine efficacy across different age groups.

02 Neurological Disorders

Groundbreaking research into neurodegenerative conditions, with particular focus on early intervention strategies for Alzheimer's and Parkinson's disease treatment approaches.

  • Early Alzheimer's Disease
  • Parkinson's Disease Therapeutics
  • Myasthenia Gravis Management

Studies aim to slow disease progression and improve patient outcomes.

03 Autoimmune & Inflammatory Conditions

Comprehensive trials examining new treatments for various inflammatory disorders, including psoriasis, arthritis, and inflammatory bowel diseases.

  • Psoriatic Arthritis
  • Crohn's Disease
  • Atopic Dermatitis

Focus on developing targeted therapies for chronic inflammatory conditions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.